{
    "relation": [
        [
            "Published Date",
            "May 28, 2015",
            "Oct 14, 2014",
            "May 13, 2014",
            "Apr 17, 2014",
            "Nov 18, 2013",
            "Aug 19, 2013",
            "Jan 31, 2013",
            "Aug 2, 2012",
            "Jul 16, 2012",
            "Nov 2, 2011",
            "Sep 7, 2011",
            "Apr 27, 2010"
        ],
        [
            "Version",
            "20 (current)",
            "18",
            "17",
            "11",
            "8",
            "7",
            "6",
            "5",
            "4",
            "3",
            "2",
            "1"
        ],
        [
            "Files",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download"
        ]
    ],
    "pageTitle": "DailyMed - SOLIRIS- eculizumab injection, solution, concentrate",
    "title": "",
    "url": "http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988312.76/warc/CC-MAIN-20150728002308-00066-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 59227671,
    "recordOffset": 59177371,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{63212=Five single-arm studies [four prospective (aHUS Studies 1, 2, 4 and 5) and one retrospective (aHUS Study 3)] evaluated the safety and efficacy of Soliris for the treatment of aHUS.\u00a0\u00a0 Patients with aHUS received meningococcal vaccination prior to receipt of Soliris or received prophylactic treatment with antibiotics until 2 weeks after vaccination.\u00a0 \u00a0In all studies, the dose of Soliris in adult and adolescent patients was 900\u00a0mg every 7 \u00b1 2 days for 4 weeks, followed by 1200 mg 7 \u00b1 2 days later, then 1200 mg every 14 \u00b1 2 days thereafter.\u00a0 The dosage regimen for pediatric patients weighing less than 40 kg enrolled in aHUS Study 3 and Study 5 was based on body weight [see Dosage and Administration (2.2)]. Efficacy evaluations were based on thrombotic microangiopathy (TMA) endpoints., 44763=2. At data cut-off (April 20, 2012)., 159718=To report SUSPECTED ADVERSE REACTIONS, contact Alexion Pharmaceuticals, Inc. at 1-888-SOLIRIS (1-888-765-4747) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch., 26216=1244 (282-7164), 164351=Dosage and Administration (2.4)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a04/2014, 20641=1. through data cutoff (October 12, 2012)., 157941=Revised: 4/2014, 2627=Call your doctor for medical advice about side effects.\u00a0 You may report side effects to FDA at 1-800-FDA-1088., 15764=US License Number 1743, 44849=1. At data cut-off (September 8, 2010)., 1517=Revised: 04/2014, 26332=1510 (282-7164), 53136=1.At data cut-off (September 8, 2010)., 53051=2.At data cut-off (April 20, 2012).}",
    "textBeforeTable": "Number of versions: 12 SOLIRIS- eculizumab injection, solution, concentrate View Label Archives for this drug View Label Archives, RxNorm, Get Label RSS Feed More Info on this Drug Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary Related Resources Boxed Warnings, Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk Safety (also available in the left menu) Find additional resources Close All Sections View All Sections Close Labeler -\u00a0Alexion Pharmaceuticals Inc. (789359510) 04/02/2007 BLA125166 BLA Marketing End Date Marketing Start Date Application Number or Monograph Citation Marketing Category Marketing Information 30 mL in 1 VIAL; Type 0: Not a Combination Product 1",
    "textAfterTable": "RxNorm SOLIRIS- eculizumab injection, solution, concentrate RxCUI RxNorm NAME RxTTY 1 700384 eculizumab 300 MG in 30 ML Injection PSN 2 700384 30 ML eculizumab 10 MG/ML Injection SCD 3 700384 eculizumab 300 MG per 30 ML Injection SY 4 700387 Soliris 300 MG in 30 ML Injection PSN 5 700387 30 ML eculizumab 10 MG/ML Injection [Soliris] SBD 6 700387 30 ML Soliris 10 MG/ML Injection SY 7 700387 Soliris 300 MG per 30 ML Injection SY Get Label RSS Feed for this Drug SOLIRIS- eculizumab injection, solution, concentrate To receive this label RSS feed Copy the URL below and paste it into your RSS Reader application. https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722 To receive all DailyMed Updates for the last seven days Copy the URL below and paste it into your RSS Reader application. https://dailymed.nlm.nih.gov/dailymed/rss.cfm What will I get with the DailyMed RSS feed? DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed. DailyMed will deliver this notification to",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}